GB201013513D0 - Formulations - Google Patents

Formulations

Info

Publication number
GB201013513D0
GB201013513D0 GBGB1013513.5A GB201013513A GB201013513D0 GB 201013513 D0 GB201013513 D0 GB 201013513D0 GB 201013513 A GB201013513 A GB 201013513A GB 201013513 D0 GB201013513 D0 GB 201013513D0
Authority
GB
United Kingdom
Prior art keywords
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1013513.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novacta Biosystems Ltd
Original Assignee
Novacta Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Ltd filed Critical Novacta Biosystems Ltd
Priority to GBGB1013513.5A priority Critical patent/GB201013513D0/en
Publication of GB201013513D0 publication Critical patent/GB201013513D0/en
Priority to CN201180038723.5A priority patent/CN103108628B/zh
Priority to MX2013001470A priority patent/MX2013001470A/es
Priority to JP2013523659A priority patent/JP5865374B2/ja
Priority to EP11749878.2A priority patent/EP2603204A2/en
Priority to CA2807206A priority patent/CA2807206A1/en
Priority to EA201291463A priority patent/EA024344B1/ru
Priority to US13/816,063 priority patent/US9192569B2/en
Priority to PCT/GB2011/001191 priority patent/WO2012020219A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1013513.5A 2010-08-11 2010-08-11 Formulations Ceased GB201013513D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1013513.5A GB201013513D0 (en) 2010-08-11 2010-08-11 Formulations
CN201180038723.5A CN103108628B (zh) 2010-08-11 2011-08-09 用于输注b型羊毛硫抗生素的制剂
MX2013001470A MX2013001470A (es) 2010-08-11 2011-08-09 Formulaciones para infusion de lantibioticos de tipo b
JP2013523659A JP5865374B2 (ja) 2010-08-11 2011-08-09 Ｂ型ランチビオティックの点滴用製剤
EP11749878.2A EP2603204A2 (en) 2010-08-11 2011-08-09 Formulations for infusion of type b lantibiotics
CA2807206A CA2807206A1 (en) 2010-08-11 2011-08-09 Formulations for infusion of type b lantibiotics
EA201291463A EA024344B1 (ru) 2010-08-11 2011-08-09 Составы для инфузии лантибиотиков типа b
US13/816,063 US9192569B2 (en) 2010-08-11 2011-08-09 Formulations for infusion of type B lantibiotics
PCT/GB2011/001191 WO2012020219A2 (en) 2010-08-11 2011-08-09 Formulations for infusion of type b lantibiotics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1013513.5A GB201013513D0 (en) 2010-08-11 2010-08-11 Formulations

Publications (1)

Publication Number Publication Date
GB201013513D0 true GB201013513D0 (en) 2010-09-22

Family

ID=42931511

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1013513.5A Ceased GB201013513D0 (en) 2010-08-11 2010-08-11 Formulations

Country Status (9)

Country Link
US (1) US9192569B2 (https=)
EP (1) EP2603204A2 (https=)
JP (1) JP5865374B2 (https=)
CN (1) CN103108628B (https=)
CA (1) CA2807206A1 (https=)
EA (1) EA024344B1 (https=)
GB (1) GB201013513D0 (https=)
MX (1) MX2013001470A (https=)
WO (1) WO2012020219A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4067368A1 (en) 2016-06-01 2022-10-05 Athira Pharma, Inc. Compounds
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
CN109620979B (zh) * 2018-12-29 2020-09-01 福建师范大学 低离子休克提高氨基糖苷类抗生素杀灭持留菌效率的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1013513A (en) 1963-03-25 1965-12-15 Watney Combe Reid & Co Ltd Improvements in and relating to hopping beer
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (https=) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
EP0700998B1 (en) 1994-09-12 2003-11-26 Aventis Pharma Deutschland GmbH Recombinant mersacidin and a method for production
CN1138560C (zh) 1995-06-23 2004-02-18 Ambi股份有限公司 控制对抗生素耐药的革兰氏阳性细菌的方法和治疗感染的方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
DE19745583A1 (de) 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
JP2004501191A (ja) 2000-06-28 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド カルベジロール
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
JP2006502713A (ja) 2002-10-10 2006-01-26 モリケム メディシンズ， インコーポレイテッド デュラマイシンをコードする核酸
MXPA05004121A (es) * 2002-10-18 2006-02-17 Molichem Medicines Inc Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
ES2281808T3 (es) 2003-07-18 2007-10-01 Vicuron Pharmaceuticals, Inc. Antibiotico 107891, sus factores a1 y a2, composiciones y sales farmaceuticamente aceptables y uso del mismo.
US20050271650A1 (en) 2004-02-17 2005-12-08 Cellmatrix, Inc. Method and composition for angiogenesis inhibition
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
JP2009509519A (ja) 2005-09-27 2009-03-12 ノヴァクタ バイオシステムズ リミティッド ランチビオティックメルサシジンの変種およびそれらの使用
GB0600928D0 (en) * 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
KR20120038021A (ko) 2006-10-27 2012-04-20 화이자 프로덕츠 인코포레이티드 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법
CA2690267A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
WO2010058238A1 (en) 2008-11-24 2010-05-27 Sentinella Pharmaceuticals, Inc. ("Sentinella") Lantibiotic carboxyamide derivatives with enhanced antibacterial activity
SI2387580T1 (sl) 2009-01-14 2014-11-28 Novacta Biosystems Limited Deoksiaktagardinski derivati
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
MX2011008043A (es) 2009-02-04 2011-08-17 Novacta Biosystems Ltd Derivados de actagardina.
JP5852966B2 (ja) * 2010-02-02 2016-02-03 ノヴァクタ バイオシステムズ リミティッド ランチビオティックの塩
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
US20130171252A1 (en) 2010-07-14 2013-07-04 Novacta Biosystems Limited Formulation Comprising a Type B Lantibiotic

Also Published As

Publication number Publication date
CN103108628B (zh) 2015-08-05
MX2013001470A (es) 2013-05-14
WO2012020219A3 (en) 2012-04-05
JP5865374B2 (ja) 2016-02-17
CN103108628A (zh) 2013-05-15
JP2013533304A (ja) 2013-08-22
WO2012020219A2 (en) 2012-02-16
US20130137630A1 (en) 2013-05-30
EP2603204A2 (en) 2013-06-19
US9192569B2 (en) 2015-11-24
EA201291463A1 (ru) 2013-07-30
EA024344B1 (ru) 2016-09-30
CA2807206A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
IL223206A0 (en) Vaccine formulations
IL221409A0 (en) Abuse-resistant formulations
PL2468361T3 (pl) Formulacje wildagliptyny
PL2359816T3 (pl) Formulacje aripiprazolu
ZA201300194B (en) Formulations
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
GB201110278D0 (en) Formulations
ZA201300196B (en) Formulations
GB201006326D0 (en) Formulation
GB201018649D0 (en) Formulations
GB201012589D0 (en) Formulations
GB201018645D0 (en) Formulations
GB201018647D0 (en) Formulations
GB201010494D0 (en) Formulations
GB201008470D0 (en) Formulations
GB201008358D0 (en) Formulations
GB201007959D0 (en) Formulations
GB201007702D0 (en) Formulations
GB201018648D0 (en) Formulations
GB201005587D0 (en) Novel formulations
GB201002000D0 (en) Formulation
GB201005992D0 (en) Formulation
GB201001978D0 (en) Formulation
GB201105410D0 (en) Formulations

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)